Pancreatic neuroendocrine tumors: a review.

Neuroendocrine tumors (NETs) are a rare and heterogeneous group of tumors with widely varying morphologies and behaviors. Due to their rarity and heterogeneity, progress in improving their treatment has been slow. However, in recent years there have been advances both in their characterization and in the available treatment options. This review will attempt to address these, with particular reference to pancreatic NETs. Pancreatic NETs are a subset of NETs, previously known as islet cell tumors, which appear to be a distinct biological entity, responding differently to systemic treatments compared with NETs arising elsewhere in the GI tract.

[1]  F. Spada,et al.  Everolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients with Neuroendocrine Tumors: A 5-Year Update , 2017, Neuroendocrinology.

[2]  S. Ricci,et al.  Everolimus in combination with octreotide long‐acting repeatable in a first‐line setting for patients with neuroendocrine tumors: An ITMO group study , 2014, Cancer.

[3]  T. Meyer,et al.  Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours. , 2014, European journal of cancer.

[4]  N. Adsay,et al.  Neuroendocrine Tumors of the Pancreas: Current Concepts and Controversies , 2014, Endocrine Pathology.

[5]  I. Drozdov,et al.  Gut neuroendocrine tumor blood qPCR fingerprint assay: characteristics and reproducibility , 2013, Clinical chemistry and laboratory medicine.

[6]  A. Lenzi,et al.  Somatostatin Analogs Therapy in Gastroenteropancreatic Neuroendocrine Tumors: Current Aspects and New Perspectives , 2013, Front. Endocrinol..

[7]  J. Meyerhardt,et al.  A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor , 2013, Cancer.

[8]  M. Seshadri,et al.  Current understanding of the molecular biology of pancreatic neuroendocrine tumors. , 2013, Journal of the National Cancer Institute.

[9]  C. Thirlwell,et al.  Neuroendocrine tumours: cracking the epigenetic code. , 2013, Endocrine-related cancer.

[10]  G. Poston,et al.  The surgical management of neuroendocrine tumour hepatic metastases. , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  L. Kvols,et al.  Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. , 2012, Endocrine-related cancer.

[12]  K. Öberg,et al.  Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Jeffrey W. Clark,et al.  Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  H. Döhner,et al.  Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  B. Wiedenmann,et al.  Prognostic relevance of circulating PIGF levels in patients with neuroendocrine tumors. , 2012 .

[16]  Mohid S. Khan,et al.  Circulating tumor cells as prognostic and predictive markers in neuroendocrine tumors. , 2012 .

[17]  M. Falconi,et al.  ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors , 2011, Neuroendocrinology.

[18]  E. Baudin,et al.  ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary , 2011, Neuroendocrinology.

[19]  J. Hainsworth,et al.  Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study , 2011, The Lancet.

[20]  R. McLendon,et al.  Altered Telomeres in Tumors with ATRX and DAXX Mutations , 2011, Science.

[21]  M. Choti,et al.  Surgery Versus Intra-arterial Therapy for Neuroendocrine Liver Metastasis: A Multicenter International Analysis , 2011, Annals of Surgical Oncology.

[22]  Matthias Briel,et al.  Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Michael A. Choti,et al.  DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors , 2011, Science.

[24]  E. D. de Vries,et al.  Everolimus for advanced pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[25]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[26]  D. Coppola,et al.  First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas , 2011, Cancer.

[27]  D. Breen,et al.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs) , 2005, Gut.

[28]  I. Modlin,et al.  A Nomogram to Assess Small-Intestinal Neuroendocrine Tumor (‘Carcinoid’) Survival , 2010, Neuroendocrinology.

[29]  R. Jensen,et al.  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. , 2010, Pancreas.

[30]  A. Hackshaw,et al.  Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours , 2010, British Journal of Cancer.

[31]  C. Schade-Brittinger,et al.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Jeffrey W. Clark,et al.  O-Methylguanine DNA Methyltransferase Deficiency and Response toTemozolomide-BasedTherapy in Patients with Neuroendocrine Tumors , 2008 .

[33]  B. Skogseid,et al.  Prognostic Factors and Survival in 324 Patients with Pancreatic Endocrine Tumor Treated at a Single Institution , 2008, Clinical Cancer Research.

[34]  G. Petersen,et al.  Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  S. Willich,et al.  Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors , 2008, Cancer.

[36]  E. Berber,et al.  Local Recurrence After Laparoscopic Radiofrequency Ablation of Liver Tumors: An Analysis of 1032 Tumors , 2008, Annals of Surgical Oncology.

[37]  Manal M. Hassan,et al.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  C. Nutting,et al.  Radioembolization for Unresectable Neuroendocrine Hepatic Metastases Using Resin 90Y-Microspheres: Early Results in 148 Patients , 2008, American journal of clinical oncology.

[39]  E. Krenning,et al.  Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  M. Essen,et al.  et al Treatment with the radiolabeled somatostatinanalog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival Journal of Clinical Oncology : , 2008 .

[41]  Douglas B. Evans,et al.  Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression‐free survival among patients with low‐grade neuroendocrine tumors , 2007, Cancer.

[42]  R. Bale,et al.  68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT , 2007, Journal of Nuclear Medicine.

[43]  J. Hainsworth,et al.  Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Jeffrey W. Clark,et al.  Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Douglas B. Evans,et al.  Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  T. de Baère,et al.  The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? , 2004, European journal of cancer.

[47]  I. Modlin,et al.  A 5‐decade analysis of 13,715 carcinoid tumors , 2003, Cancer.

[48]  D. Haller,et al.  Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  B. B. Rawdon,et al.  The origin of gut and pancreatic neuroendocrine (APUD) cells—the last word? , 1998, The Journal of pathology.